Intrinsiqq
Vaxcyte, Inc. logo

Vaxcyte, Inc.

PCVX

⊜ Compare

We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are re-engineering the way highly complex vaccines are made through the XpressCF cell-free protein synthesis platform.

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$9.77B
EPS-$7.64
P/E-8.60
P/FCF-10.93
EV/EBITDA-7.21
FCF Yield–
Div. Yield–
Net Debt/FCF1.5x
Vaxcyte, Inc. intrinsic value
52-Week Range
$40.32$73.82

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$1.06B

▼ -65.2% YoY

Op. Margin

–

ROIC

-31.30%

▼ -4.2pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$894M

▼ -40.9% YoY

Op. Cash Flow (TTM)

-$881M

▼ -44.8% YoY

Net Debt

-$1.37B

Net Cash Position

Cash & Equiv.

$1.49B

Continue Research

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with PCVX

CompareIntrinsic value
RGNXRegenxbio Inc.
$7.71+1.05%40
FDMT4D Molecular Therapeutics, Inc.
$12.28+2.76%40
AGENAgenus Inc.
$6.97+4.50%46
VXRTVaxart Inc.
$0.40+0.00%84
IOVAIovance Biotherapeutics, Inc.
$8.70-1.47%10
DNAGinkgo Bioworks Holdings Inc.
$11.65+8.27%15
ADMAAdma Biologics Inc.
$10.48-5.67%82
IMCRImmunocore Holdings plc
$29.23-2.66%40

Held by ETFs

PCVX is in 86 US ETFs. The largest of them, with PCVX's weight in each:

Vaxcyte (PCVX) in two numbers

Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-8.60
Negative: a loss over the last twelve months. Price to free cash flow -10.93.
Financials

Questions about Vaxcyte

Does Vaxcyte (PCVX) pay a dividend?

No. Vaxcyte (PCVX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 3 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in PCVX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PCVX

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.